P25774 (CATS_HUMAN) Homo sapiens (Human)

Cathepsin S UniProtKBInterProSTRINGInteractive Modelling

331 aa; Sequence (Fasta) ; (Isoform 2)

Available Structures

59 Experimental Structures

DescriptionPDB IDOligo-stateRangeLigands
Structure of Cathepsin S in complex with Compound 20bhomo-2-mer113-331
EDO;FLC;SO4;Q1N;
Assess
Structure of Cathepsin S in complex with Compound 14homo-2-mer113-331
FLC;Q1E;SO4;
Assess
Structure of Cathepsin S in complex with Compound 1homo-2-mer114-331
SO4; 32×EDO;DMS;Q1K;FLC;
Assess
Structure of Cathepsin S in complex with Compound 2homo-2-mer114-331
ACT;Q1H;SIN;MLA;
Assess
Structure of Cathepsin S in complex with Compound 3homo-2-mer114-331
Q1Q;
Assess
THE CRYSTAL STRUCTURE OF A CYS25ALA MUTANT OF HUMAN PROCATHEPSIN Smonomer18-331
Assess
Cathepsin S in complex with non covalent arylaminoethyl amide.monomer112-331
SO4;
Assess
Cathepsin S in complex with non-covalent 2-(Benzoxazol-2-ylamino)-acetamidemonomer112-331
GNF;
Assess
Crystal Structure of Cathepsin S in complex with a Nonpeptidic Inhibitor.monomer114-331
H7J;P15;
Assess
Crystal Structure of Human Cathepsin S Bound to a Non-covalent Inhibitor.monomer114-331
2FZ;
Assess
Human Cathepsin S with Inhibitor CRA-26871monomer114-331
C71;
Assess
Cathepsin S with nitrile inhibitormonomer114-331
CRJ;
Assess
Crystal structure of human Cathepsin-S with bound ligandmonomer114-331
BFV;
Assess
Crystal structure of human Cathepsin-S with bound ligandmonomer114-331
N2D;
Assess
Crystal structure of human Cathepsin-S with bound ligandmonomer114-331
BGY;
Assess
Crystal Structure of Human Cathepsin S Bound to a Non-covalent Inhibitormonomer114-331
SO4;2FC;
Assess
Crystal structure of human Cathepsin-S with bound ligandmonomer114-331
BQJ;
Assess
Crystal structure of human Cathepsin-S with bound ligandmonomer114-331
BQS;EOH;
Assess
Crystal structure of human Cathepsin-S with bound ligandmonomer114-331
BHJ;SO4;
Assess
Human Cathepsin S with Inhibitor CRA-27566monomer114-331
CRL;
Assess
Crystal structure of human Cathepsin-S with bound ligandmonomer114-331
B9Y;
Assess
Crystal structure of human Cathepsin-S with bound ligandmonomer114-331
BG7;
Assess
Crystal structure of human Cathepsin-S with bound ligandmonomer114-331
BJY;SO4;
Assess
Crystal structure of human Cathepsin-S with bound ligandmonomer114-331
BC7;
Assess
Crystal structure of human Cathepsin-S with bound ligandmonomer114-331
B9S;
Assess
Crystal structure of human Cathepsin-S with bound ligandmonomer114-331
BCJ;
Assess
Crystal structure of human Cathepsin-S with bound ligandmonomer114-331
B8V;
Assess
Crystal structure of human Cathepsin-S with bound ligandmonomer114-331
SO4;GOL;BJV;
Assess
Crystal structure of human Cathepsin-S with bound ligandmonomer114-331
SO4;BJS;
Assess
Crystal structure of human Cathepsin-S with bound ligandmonomer114-331
BHV;
Assess
Crystal structure of human Cathepsin-S with bound ligandmonomer114-331
N2A;
Assess
Crystal structure of human Cathepsin-S with bound ligandmonomer114-331
BGJ;SO4;
Assess
Crystal structure of human Cathepsin-S with bound ligandmonomer114-331
BAJ;
Assess
Crystal structure of human Cathepsin-S with bound ligandmonomer114-331
BJD;
Assess
Cathepsin S in complex with a covalent inhibitor with an aldehyde warheadmonomer115-331
O64;DMS;
Assess
4-(3-Trifluoromethylphenyl)-pyrimidine-2-carbonitrile as cathepsin S inhibitors: N3, not N1 is crit…monomer115-331
PEG;DMS;935;93N;
Assess
The structure of cathepsin S with a novel 2-arylphenoxyacetaldehyde inhibitor derived by the Substr…monomer115-331
SO4;TF5;PEU;
Assess
Human Cathepsin S with Inhibitor CRA-29728monomer115-331
C28;
Assess
Crystal structures of Cathepsin S inhibitor complexesmonomer115-331
C4P;
Assess
Crystal Structure of Cathepsin S in complex with a Zinc mediated non-covalent arylaminoethyl amidemonomer115-331
ZN;CL;GNQ;
Assess
Human Cathepsin S with CRA-27934, a Nitrile Inhibitormonomer115-331
CRV;
Assess
Dipeptide Nitrile Inhibitor Bound to Cathepsin S.monomer115-331
BLN;
Assess
Crystal Structure of Cathepsin S in complex with a Nonpeptidic Inhibitor (Hexagonal spacegroup)monomer115-331
SO4;H7J;
Assess
6-Phenyl-1H-imidazo[4,5-c]pyridine-4-carbonitrile as cathepsin S inhibitorsmonomer115-331
EF3;DMS;
Assess
Cathepsin S complexed with Compound 15monomer115-331
Y11;
Assess
Crystal structures of Cathepsin S inhibitor complexesmonomer115-331
C1P;
Assess
Human Cathepsin S with inhibitor CRA-16981monomer115-331
MO9;
Assess
Cathepsin S complexed with Compound 26monomer115-331
Y14;
Assess
Cathepsin S complexed with Compound 8monomer115-331
Y15;
Assess
Crystal structure of human Cathepsin-S with bound ligandmonomer115-331
BJD;SO4;GOL;
Assess
Pyrazole-based Cathepsin S Inhibitors with Arylalkynes as P1 Binding Elementsmonomer115-331
599;
Assess
Crystal Structure of Cys25Ser mutant of human cathepsin Smonomer115-331
Assess
Mutant Human Cathepsin S with irreversible inhibitor CRA-14013monomer115-331
BCQ;
Assess
Crystal structure of human Cathepsin-S with bound ligandmonomer115-331
BQP;
Assess
Human cathepsin S mutant with vinyl sulfone inhibitor CRA-14009monomer115-331
MQQ;
Assess
Crystal structure of human Cathepsin-S with bound ligandmonomer115-331
SO4;BJJ;
Assess
Crystal structure of human Cathepsin-S with bound ligandmonomer115-331
B8J;
Assess
Crystal structure of human Cathepsin-S with bound ligandmonomer115-331
B8Y;
Assess
Crystal structure of human Cathepsin-S with bound ligandmonomer115-331
B8S;
Assess

1 SWISS-MODEL model

TemplateOligo-stateQMEANDisCoRangeLigandsTrg-Tpl Seq id (%)
2c0y.1.Amonomer0.9118-331
99.68
Assess

1 SWISS-MODEL model built on isoform sequence

TemplateIsoformOligo-stateQMEANDisCoRangeLigandsTrg-Tpl Seq id (%)
Isoform 22c0y.1.Amonomer0.8620-281
95.80
Assess